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Wnt9a deficiency discloses 
a repressive role of Tcf7l2 on 
endocrine differentiation in the 
embryonic pancreas
G. Pujadas1,2,3, S. Cervantes1,2, A. Tutusaus1, M. Ejarque1,2,3, L. Sanchez1, A. García1,2, 
Y. Esteban1,2, L.  Fargas4, B. Alsina4, C. Hartmann5, R. Gomis1,2,3 & R. Gasa1,2
Transcriptional and signaling networks establish complex cross-regulatory interactions that drive 
cellular differentiation during development. Using microarrays we identified the gene encoding the 
ligand Wnt9a as a candidate target of Neurogenin3, a basic helix-loop-helix transcription factor that 
functions as a master regulator of pancreatic endocrine differentiation. Here we show that Wnt9a 
is expressed in the embryonic pancreas and that its deficiency enhances activation of the endocrine 
transcriptional program and increases the number of endocrine cells at birth. We identify the gene 
encoding the endocrine transcription factor Nkx2-2 as one of the most upregulated genes in Wnt9a-
ablated pancreases and associate its activation to reduced expression of the Wnt effector Tcf7l2. 
Accordingly, in vitro studies confirm that Tcf7l2 represses activation of Nkx2-2 by Neurogenin3 and 
inhibits Nkx2-2 expression in differentiated β-cells. Further, we report that Tcf7l2 protein levels decline 
upon initiation of endocrine differentiation in vivo, disclosing the downregulation of this factor in the 
developing endocrine compartment. These findings highlight the notion that modulation of signalling 
cues by lineage-promoting factors is pivotal for controlling differentiation programs.
In the developing pancreas, multipotent pancreatic progenitors give rise to endocrine (α , β , δ , PP and ε ) and exo-
crine (acinar and ductal) cell lineages through the sequential and coordinated activation-inhibition of a number 
of transcription factors. The transcription factor Neurogenin3 (Neurog3) functions as a master regulator of endo-
crine cell development. In the mouse, the peak of Neurog3 expression occurs between embryonic days (E)13.5 
and 16.5, a stage known as the secondary transition when major pancreatic differentiation waves take place. 
Expression of Neurog3 instructs bipotent duct/endocrine progenitors located in the trunk domain of the pancre-
atic epithelium to adopt an endocrine cell fate. Neurog3 functions as a potent transcriptional activator that initi-
ates the endocrine transcriptional program by inducing the expression of several transcription factors, including 
Pax4, Nkx2-2, NeuroD1 or Insm1, which will carry on the differentiation process (for extensive reviews see1,2).
The canonical Wnt pathway is transduced through stabilized (dephosphorylated) β -catenin protein that 
translocates to the nucleus and cooperates with lymphoid-enhancer-binding factor T-cell factor (LEF/TCF) 
DNA-binding proteins to activate Wnt-dependent genes. There is evidence to suggest that canonical Wnt par-
ticipates in pancreas organogenesis, including the dynamic regulation of canonical Wnt ligands and receptors 
within the developing pancreas3,4, the presence of dephosphorylated β -catenin in the pancreatic epithelium from 
E11.5 to E15.54–6 and the identification of cells positive for Wnt reporter gene expression in embryonic pancre-
ases of mouse reporter lines7,8. At early stages, activation of Wnt has been shown to prevent pancreas develop-
ment, possibly through inhibition of organ specification3,9. Later, Wnt/β -catenin is needed for the proliferation 
of pancreatic progenitors and proper organ growth. Thus, ablation of β -catenin5,6 or the ligand Wnt7b10 and 
transgenic expression of Wnt signalling inhibitors4 result in severe organ hypoplasia whilst, conversely, β -catenin 
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stabilization leads to increased organ size9. More disputed is the role of Wnt signals in the differentiation of the 
pancreatic lineages. While some studies ascribe to this pathway an exclusive role in exocrine development5,6,9, 
others indicate additional roles in the endocrine compartment4,7. In support of the participation of Wnt signals 
in endocrine development, expression profile data from isolated Neurog3+ cells and gain-of-function models 
identified the Wnt pathway, amongst other intercellular signalling pathways, as a potential target of Neurog311,12. 
To date, only non-canonical planar cell polarity/Wnt signalling has been connected to endocrine differentiation 
downstream of Neurog311.
Using gene expression profiling in a Neurog3-dependent endocrine differentiation cell model13, we identified 
the gene encoding the Wnt ligand Wnt9a, formerly Wnt14, as a potential Neurog3 target. Wnt9a signalling has 
been shown to participate in joint formation where it influences cell fate assignment by suppressing chondro-
cyte differentiation from bi-potential chondro-synovio progenitors14–17. In the zebrafish, the Wnt9a homolog 
was identified in the central nervous system, pro-nephric ducts and sensory organs and connected to palate 
development18,19. In the chicken, Wnt9a has been implicated in hepatic epithelium morphogenesis and in the 
development of the retina20. However, there are no prior reports on Wnt9a in the pancreas. Herein, we present 
in vitro and in vivo evidence of the participation of Wnt9a-dependent signalling in islet cell development. We 
show that Wnt9a loss increases the formation of pancreatic endocrine cells and present the Wnt effector Tcf7l2 as 
a likely mediator of these effects. These findings highlight the importance of the interactions between signalling 
pathways and transcriptional programs that drive endocrine cell differentiation.
Results
Neurog3 induces the Wnt9a gene in vitro. The mouse mPAC L20 cell line has been previously used to 
model Neurog3-dependent induction of the endocrine differentiation program21. Using gene expression arrays13, 
we identified several Wnt-related genes including ligands, receptors, modulators, effectors and targets, whose 
expression was regulated by Neurog3 in this model (Supplementary Table S1). These findings led us to investigate 
the involvement of Wnt signals in endocrine cell development.
Two ligands emerged as potential Neurog3 targets in our microarray data set, Wnt9a and Wnt7b (Table S1 and 
Fig. 1a). Wnt7b has been recently ascribed a role in pancreatic progenitor proliferation before the secondary tran-
sition10, hence we focused on Wnt9a as a potential novel Neurog3 target. We conducted time and dose curves for 
Wnt9a induction and confirmed early activation of this gene upon Neurog3 expression (Fig. 1b,c). To assess the 
specificity of the Neurog3 actions, we investigated the effects of other pancreatic and neuronal lineage-promoting 
bHLH factors on Wnt9a mRNA levels. We found that NeuroD1 (neuroendocrine) and Ascl1 (neural) activated 
Wnt9a gene expression at similar levels as Neurog3, whereas the exocrine bHLH factors Ptf1a and Mist1 failed to 
do so (Fig. 1d), placing the Wnt9a gene downstream of lineage-driving neuroendocrine bHLH factors. To further 
delineate the position of Wnt9a in the endocrine program, we assessed the effects of the endocrine differentiation 
factors Pax4, Nkx6-1 and Nkx2-2, which are upregulated downstream of Neurog3. When expressed alone, they 
had no effect, but Pax4 and Nkx6-1 potentiated Neurog3-dependent transactivation of the Wnt9a gene (Fig. 1e). 
Neurog3 also activated the Wnt9a gene in non-pancreatic cell contexts such as teratocarcinoma P19 cells and 3T3 
fibroblasts (Supplementary Fig. S1), thus supporting the sufficiency of Neurog3 to increase Wnt9a expression in 
vitro.
Wnt9a is expressed in the embryonic pancreas. Prior to investigating the role of Wnt9a during endo-
crine cell development in vivo, we examined the presence of Wnt9a transcripts in the developing mouse pancreas. 
We performed conventional RT-PCR using RNA from E13.5-E17.5 pancreatic buds and confirmed that Wnt9a 
was expressed in the pancreas during the secondary transition (Fig. 2a). To assess its kinetics of expression, we 
used qRT-PCR and found that the Wnt9a message was expressed at low and relatively constant levels, in sharp 
contrast to Wnt7b, throughout the stages studied (Fig. 2b).
In lieu of a suitable antibody we studied lacZ activity as readout for Wnt9a expression in pancreases from 
Wnt9aLacZ mice16. Although we were unable to detect a reproducible signal in heterozygous Wnt9aLacZ/+ pan-
creases (likely due to low expression levels), we did observe positive signal in central areas of the pancreatic 
epithelium in knockout Wnt9aLacZ/LacZ pancreases at E14.5-E15.5 after lengthy X-gal staining (Fig. S2). To obtain 
additional evidence for the expression of the Wnt9a gene in pancreatic epithelial cells, we obtained E14.5 pan-
creases from Pdx1-Cre; Rosa26:tdTomato (tdT) mice, isolated tdT+ cells by FACS and verified the presence of 
Wnt9a transcripts in Pdx1+ cells (Fig. 2c,d). Of note, Wnt9a mRNA was also detected in Pdx1- cells (data not 
shown), indicating that this gene is also expressed in the pancreatic mesenchyme as described for other Wnt lig-
ands3. We next isolated tdT+ cells from Neurog3-Cre; Rosa26:tdT pancreases at E15.5 and established expression 
of Wnt9a in endocrine progenitor cells and their descendants (Fig. 2c,d). Altogether, these observations place 
Wnt9a at the right time and place to play an autonomous role in pancreatic endocrine cell differentiation.
Wnt9a ablation leads to increased pancreatic endocrine cell numbers. To address the function 
of Wnt9a during endocrine pancreatic development, we undertook a loss-of-function approach and character-
ized the pancreatic phenotype of Wnt9a knockout mice generated by crossing Wnt9aLacZ/+ mice. Homozygous 
Wnt9aLacZ/LacZ (hereafter Wnt9a−/−) pups fail to thrive and die within the first hours of birth of undefined causes16. 
Pancreas weight, in absolute values (WT: 8.40 ± 0.59mg;  Wnt9a−/−: 7.83 ± 0.82 mg) and as percentage of body 
weight (WT: 7.61 ± 0.52; Wnt9a−/−: 6.90 ± 0.2), was similar between Wnt9a−/− and wild-type (WT) newborn 
littermates. Similarly, there were no observable differences in pancreas gross morphology and architecture 
(Fig. 3a,b), demonstrating that Wnt9a is not necessary for pancreas formation and growth. Next we stained pan-
creas sections from E18.5 embryos with antibodies against insulin (β -cells), glucagon (α -cells) and somatostatin 
(δ -cells) confirming the presence and normal spatial cell disposition of these islet lineages in Wnt9a−/− pancreases 
(Fig. 3c). We performed morphometric analysis to evaluate the relative abundance of these cell types and found 
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that β -cells were increased by 1.4-fold, α -cells by 2.2-fold and δ -cells by 2.1-fold (pancreatic areas analyzed: 
11.12 ± 1.27 mm2 for Wnt9a−/− and 11.45 ± 1.28 mm2 for WT) in Wnt9a−/− pancreases relative to WT (Fig. 3d), 
thus revealing that Wnt9a loss leads to higher endocrine cell numbers. Unfortunately, early postnatal lethality of 
Wnt9a knockouts prevented assessment of the impact of this phenotype on glucose homeostasis.
Figure 1. Regulation of the Wnt9a gene by NEUROG3 in vitro. mPAC cells were treated with the indicated 
adenoviruses and total cellular RNA was extracted 48 h after virus treatment. (a) mRNAs encoding the indicated 
genes were assessed by conventional RT-PCR. Beta actin (Actb) was used as internal control. Cycles used were 
25 for Actb and 28 for the other genes. Representative gel image is shown. (b) mPAC cells were treated with the 
indicated moi of AdV-NEUROG3. Wnt9a and NEUROG3-transgene expression were measured by qRT-PCR 
and expressed relative to TATA-binding protein (tbp) gene expression. Bars represent mean ± SEM for at least 
3 independent experiments. (c) mPAC cells were treated with AdV-NEUROG3 (moi = 40) and collected at 
the indicated time points after addition of the virus. Wnt9a mRNA levels were quantitated by qRT-PCR. RNA 
levels for NeuroD1, as a control for a late Neurog3 target, were also assayed. Expression was normalized with 
tbp. To facilitate comparisons, for each gene the time point with highest expression was assigned a value of 100, 
and other time points expressed relative to this one. Symbols represent mean for 2 independent experiments. 
Note that Wnt9a mRNA reaches highest levels 12h after virus treatment. (d,e) Wnt9a mRNA levels were 
quantitated by qRT-PCR and expressed relative to tbp gene expression. Bars represent mean ± SEM for at least 3 
independent determinations. *p < 0.05, **p < 0.01 vs. AdV-bGal.
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As Wnt signaling controls β -cell proliferation22, we assessed whether enhanced proliferation contributed to 
increased β -cell counts at E18.5. At E17.5, the total endocrine area (measured as chromogranin A+) was higher 
in Wnt9a−/− embryos (Supplementary Fig. S3), but there were no differences in the percentage of double positive 
Ki67/insulin cells between Wnt9a−/− and WT pancreases (Supplementary Fig. S3). Therefore, increased prolifer-
ation does not appear to contribute to increased β -cell numbers in Wnt9a-deficient embryos, pointing to a role of 
Wnt9a-dependent signalling in endocrine cell genesis.
Wnt9a deficiency upregulates endocrine gene expression in the embryonic pancreas. During 
development, islet cells differentiate from bipotent duct/endocrine progenitors located in the trunk domain of 
the growing pancreas. To establish whether the increase in endocrine cells observed in E18.5 Wnt9a−/− embryos 
resulted from augmented endocrine allocation from progenitors, we determined Neurog3 transcript levels and 
counted Neurog3+ cells by immunofluorescence at E15.5, the peak of the secondary transition. We found a mod-
est increase in Neurog3 mRNA levels (Fig. 4a) whereas the number of Neurog3+ cells was unchanged (Fig. 4b), 
suggesting that Wnt9a loss does not affect endocrine specification but it may influence Neurog3 levels per cell. 
Yet, we did not detect obvious discrepancies in the relative proportion of high and low Neurog3+ expressing cells 
between mutants and controls (Fig. 4a and data not shown), thus indicating that modest increase in Neurog3 
mRNA detected upon Wnt9a loss most likely results in undetectable changes in Neurog3 protein amount, at least 
by conventional immunofluorescence.
We then used qRT-PCR to screen a panel of endocrine genes activated downstream of Neurog3. Remarkably, 
we found that mRNA levels for several of these genes, namely Nkx2-2 and Pdx1 and to a lesser extent Pax4 and 
Mnx1 were increased in E15.5 Wnt9a−/− pancreases relative to WT (Fig. 4c). Also, message levels for the early 
pan-endocrine markers Chromogranin a and b (Chga, Chgb) and the islet hormone Pancreatic Polypeptide (Ppy) 
were higher in Wnt9a−/− relative to WT (Fig. 4c). Therefore, Wnt9a ablation results in the upregulation of a subset 
of genes in the endocrine differentiation program downstream of Neurog3.
Figure 2. Expression of Wnt9a in the embryonic pancreas. (a) Total RNA was extracted from mouse 
embryonic pancreases at the indicated stages and from adult isolated mouse islets. mRNAs encoding the 
indicated genes were assayed by conventional RT-PCR. Note that expression of both Wnt5a and Wnt7b had 
been previously identified in the developing pancreas and are included for comparison purposes. Cycles used 
were 25 for Actb and 35 for the other genes. Representative gel image is shown. Lane showing non-template 
control for each transcript (blank) was run under the same experimental conditions. (b) Wnt9a and Wnt7b 
mRNA levels were quantitated by qRT-PCR and expressed relative to tbp gene expression. Each point represents 
mean ± SEM for at least 3 independent determinations. (c) Representative gel showing expression of Wnt9a 
mRNA in E15.5 total pancreas, in FACS-purified Tomato+ (Pdx1+ , epithelial) cells obtained from E14.5 
pancreas of Pdx1-Cre; Rosa26: tdTomato and in FACS-purified Tomato+ (Neurog3+ , endocrine) cells obtained 
from E15.5 pancreas of Neurog3-Cre; Rosa26: tdTomato. (d) Quantification of Wnt9a, Neurog3 and Pdx1 mRNA 
levels in total RNA from samples prepared as detailed in (c). Values are expressed relative to tbp mRNA levels in 
each sample. Bars represent mean ± SEM for at least 5 independent sorting experiments.
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To test if Wnt9a could directly impair the pro-endocrine activity of Neurog3, we generated a recombinant 
adenovirus encoding Wnt9a (AdV-Wnt9a) and ectopically expressed this ligand, alone or in combination with 
Neurog3, in mPAC cells. While Wnt9a alone had no effects on any of the genes studied (not endogenously 
expressed in mPAC cells except for Atoh8), it partially blocked activation of NeuroD1, Pax4, Nkx2-2 and Sst in 
response to Neurog3 (Fig. 4d). Remarkably, Wnt9a tended to decrease Neurog3 positive autoregulation23, which 
agrees with the finding that Neurog3 transcripts are increased in Wnt9a mutants. By contrast, Wnt9a did not affect 
Neurog3-dependent activation of Atoh8, Insm1 and IAPP. In summary, the in vivo and in vitro results support a 
negative role of Wnt9a on endocrine differentiation.
Figure 3. Pancreatic phenotype of Wnt9a knockout embryos. (a) Examination of gross morphology of 
digestive tract (a’,c’) and pancreas (b’,d’) from neonatal Wnt9a+/+ (a’,b’) and Wnt9a−/− (c’,d’) mice. Scale bar is 
5000 μ m. (b) Hematoxylin and Eosin staining was performed on paraffin sections from pancreatic tissue from 
neonatal Wnt9a+/+ and Wnt9a−/− mice. Scale bar is 200 μ m. (c) Staining for insulin (red), glucagon (green) 
and somatostatin (blue) on paraffin sections from pancreases of E18.5 Wnt9a+/+ and Wnt9a−/− embryos. Scale 
bars represent 100 μ m. (d) Morphometric quantification of the number of endocrine cells per pancreatic area 
in E18.5 Wnt9a+/+ and Wnt9a−/− embryos. Positive cells for each indicated hormone were counted separately 
and for the number of total endocrine cells combined (total). Bars represent mean ± SEM from 5 animals per 
genotype. *p < 0.05 vs Wnt9a+/+.
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To assess the specificity of the effects of Wnt9a in the endocrine compartment, we studied expression of 
acinar and ductal genes at E15.5. We found no changes in early (Cpa1, Ptf1a, Mist1) or mature (amylase) aci-
nar cell markers, thus excluding a major effect of Wnt9a in the acinar program (Supplementary Fig. S4a). In 
contrast, mRNA levels for several ductal markers (Muc1, Krt19, Spp1, Pkd2, Hnf1b) were significantly reduced 
(Supplementary Fig. S4a). This effect did not seem to be dependent on Sox9, a ductal fate determinant24, as no 
differences in either its expression or immunolocalization (Supplementary Fig. S4a,b) were observed between 
WT and Wnt9a knockout embryos. Despite decreased gene expression at E15.5, ductal differentiation appears to 
proceed normally in Wnt9a−/− embryos as indicated by normal appearance and quantification of the ductal tree 
at E17.5 using DBA staining (Supplementary Fig. S4c). A transitory embryonic ductal phenotype that resolves at 
later stages has also been described in Neurog3 mutants25.
Figure 4. Effects of Wnt9a ablation on activation of the endocrine gene expression program. (a) Total 
RNA was isolated from pancreases of E15.5 Wnt9a+/+ and Wnt9a−/− embryos. Neurog3 mRNA expression 
was assessed by qRT-PCR and normalized against tbp. Results are expressed as fold relative to levels in 
Wnt9a+/+ pancreases (value of 1). Bars represent mean ± SEM for 8 Wnt9a+/+ and 7 Wnt9a−/− embryos. 
*p < 0.05 vs Wnt9a+/+. (b) Double immunostaining for Neurog3 (red) and Pdx1 (green) on paraffin sections 
from pancreases of E15.5 Wnt9a+/+ and Wnt9a−/− embryos. Scale bars represent 50 μ m. Quantification of 
the number of Neurog3 + cells per pancreatic area is shown on the right. Bars represent mean ± SEM for 3 
animals per genotype. (c) Total RNA was isolated from pancreases of E15.5 Wnt9a+/+ and Wnt9a−/− embryos. 
mRNA levels for the indicated genes were quantitated by qRT-PCR and normalized against tbp. Results are 
expressed as fold relative to levels in Wnt9a+/+ pancreases (value of 1). Bars represent mean ± SEM for 8 
Wnt9a+/+ and 7 Wnt9a−/− embryos. *p < 0.05, **p < 0.01 vs Wnt9a+/+. (d) mPAC cells were transduced with 
the indicated adenoviruses alone or in combination. Total cellular RNA was isolated 48 h after virus treatment. 
mRNAs encoding the indicated genes were assessed by qRT-PCR and normalized relative to tbp. Expression 
in cells treated with AdV-Neurog3 was given a value of 1. Bars represent mean ± SEM for 6–8 independent 
experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs AdV-Neurog3+ AdV-bGal.
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Wnt9a-deficient embryos present diminished Tcf7l2 gene expression. Wnt9a has been regarded 
as a canonical Wnt ligand14,16,20. In initial set-up experiments using a Tcf-dependent luciferase reporter vector, we 
surveyed several pancreatic cell lines (α , β and ductal) and found that basal pathway activity and responsiveness 
to β -catenin overexpression was very low, being mPAC cells the ones that provided the best response (data not 
shown). Hence, we used these cells to interrogate whether Wnt9a signalling was transduced via Tcf factors in a pan-
creatic context. In accordance to a canonical role, Wnt9a increased the activity of the Tcf-dependent reporter vector 
and augmented endogenous mRNA levels of the bona fide Wnt targets (known to be transcriptionally induced by 
the β -catenin/Tcf pathway) axin2 and Ccnd1 in mPAC cells (Fig. 5a,b). We then tested whether Wnt9a ablation 
affected expression of these general Wnt targets in vivo using RNA from total pancreas but found no differences 
between knockout and WT embryos (Fig. 5c). Whilst these results are compatible with Wnt9a signalling affecting 
a restricted cell population in the pancreas, they expose that Wnt9a is not a principal regulator of canonical Wnt 
activity in the pancreas at E15.5. In fact, expression of several Wnt ligands has been demonstrated in the pancreas 
at this stage, which could have redundant effects on maintenance of general Wnt target expression3,10.
In addition to the above-mentioned classical Wnt targets, Wnt signalling regulates expression of genes in a cell 
context-specific manner. Among the latter, genes encoding LEF/TCF proteins, the effectors of the pathway, have 
been shown to be subject to auto-regulation in several developmental contexts26–28. Hence, we tested whether 
Wnt9a loss influenced pancreatic expression of the LEF/TCF coding genes (Tcf7, Lef1, Tcf7l1, Tcf7l2). We found 
that all four genes were expressed in the pancreas at E15.5. Remarkably, we observed a significant and specific 
reduction in the expression of Tcf7l2 in Wnt9a−/− pancreases relative to controls, while the other LEF/TCF and 
Figure 5. Involvement of TCF/LEF factors in Wnt9a-dependent signalling. (a) mPAC cells were transfected 
with the TCF-dependent luciferase reporter vector TOP-Flash (black) or its mutated version FOP-Flash (grey) 
and expression vectors for Wnt9a, Wnt3a or a mutant form of Ctnnb1 lacking aminoacids 29–48. Results 
are expressed relative to the backbone vector, normalized to 1. Bars represent mean ± SEM for at least 4 
independent experiments, each performed in duplicate *p < 0.05 and ***p < 0.001 vs backbone. (b) mPAC 
cells were transduced with an adenovirus expressing Wnt9a (AdV-Wnt9a) or AdCMV-bGal as control and 
total cellular RNA was isolated 48 h after virus treatment. mRNA levels for Axin2 and Ccnd1 were quantitated 
by qRT-PCR and normalized to tbp. Values are expressed relative to cells treated with AdV-bGal, which are 
given the value of 1. Bars represent mean ± SEM for at least 7 independent experiments. ***p < 0.001 vs bGal. 
(c) Total pancreatic mRNA from Wnt9a+/+ and Wnt9a−/− animals was collected at E15.5 and expression 
for the indicated genes was assessed by qRT-PCR and normalized with tbp. Results are presented relative to 
Wnt9a+/+ given the value of 1. Bars represent mean ± SEM for 7 Wnt9a+/+ and 6 Wnt9a−/− animals. *p < 0.05 
vs Wnt9a+/+. Note that Dkk1 mRNA was not detected in either knockout or wild-type pancreas (ND = not 
detected).
www.nature.com/scientificreports/
8Scientific RepoRts | 6:19223 | DOI: 10.1038/srep19223
β -catenin (ctnnb) coding genes were similarly expressed in WT and knockout pancreases (Fig. 5c). Collectively, 
these data disclose Tcf7l2 as a potential target/mediator of Wnt9a signalling in the developing pancreas.
Tcf7l2 negatively regulates endocrine gene expression in vitro. We next interrogated the exist-
ence of a mechanistic connection between Tcf7l2 and endocrine differentiation. Interestingly, Tcf7l2 had been 
shown to repress the Nkx2-2 gene in the developing neural system29. This evidence together with our findings 
that Wnt9a-deficient pancreases present enhanced expression of Nkx2-2 and of some of its downstream targets 
(namely Pdx1, Mnx1, Chga, Chgb and Ppy30–32) led us to postulate that Tcf7l2 might negatively regulate Nkx2-2 in 
the developing pancreas. To examine this possibility, we studied Nkx2-2 gene activation in response to Neurog3 in 
the absence or presence of Tcf7l2 in mPAC cells. Overexpressed Tcf7l2 blocked by nearly 75% Neurog3-induced 
activation of the Nkx2-2 gene (Fig. 6a). Similar results were obtained using a dominant-negative version of Tcf7l2 
that lacked the N-terminal β -catenin binding domain (data not shown), pointing to the involvement of the repres-
sor function of Tcf7l2, not its binding to β -catenin. Moreover, overexpressed Tcf7l2 reduced Neurog3-triggered 
induction of additional Neurog3 targets including Chga and Chgb (Fig. 6a).
We also asked if Tcf7l2 could inhibit Nkx2-2 gene expression in differentiated β -cells where the Nkx2-2 
gene is actively expressed. Indeed, Tcf7l2 reduced Nkx2-2 mRNA and protein levels in the β -cell line INS1E 
(Fig. 6b,c). Overexpressed Tcf7l2 also downregulated Pdx1 transcript levels (note that Pdx1 was also upregulated 
in Wnt9a-ablated pancreases) in INS1E cells (Fig. 6b). Together, these results reveal a negative effect of Tcf7l2 on 
the transactivation activity of Neurog3 and provide support to the notion that Tcf7l2 can negatively affect endo-
crine differentiation.
Tcf7l2 expression is downregulated in the differentiating endocrine compartment in vivo. In 
order to understand if Tcf7l2 could regulate Nkx2-2 and endocrine differentiation in vivo, we characterized the 
expression pattern of Tcf7l2 in the pancreas during the secondary transition. To obtain spatial information on 
Tcf7l2 expression, we used two antibodies: C9B9 raised against an epitope downstream of the β -catenin binding 
domain (Glu81 of human TCF7L2) and C48H11 raised against an epitope close to the HMG-box DNA binding 
domain (Leu330 of human TFC7L2). Both antibodies recognize long E (∼ 80KDa) and short M and S (∼ 58KDa) 
isoforms33, whilst C48H11 also recognizes a recently identified short truncated isoform (35-37KDa) that lacks 
the β -catenin binding domain and functions as a dominant negative Wnt antagonist34. We detected the presence 
of the two major groups of long and short isoforms but not the dominant negative protein in total protein extracts 
from E15.5 pancreases by immunoblot analysis (Supplementary Fig. S5a). When tested for immunostaining, only 
C48H11 provided suitable signal and revealed broad expression of Tcf7l2 throughout the pancreatic epithelium, 
marked by Pdx1 expression, at E15.5 (Supplementary Fig. S5b). As expected from the 30% reduction seen at the 
mRNA level, no readily observable differences were noted in overall Tcf7l2 expression between Wnt9a−/− and 
control pancreases using immunostaining (Supplementary Fig. S6).
However, we identified areas with very low or nearly undetectable Tcf7l2 staining both in control and mutant 
pancreases. These cells displayed high Pdx1 expression (Fig. 7a) and were insulin-positive (Fig. 7b), indicating 
that differentiating or young β -cells contain little or no Tcf7l2 protein, at least some isoform/s recognized by the 
C48H11 antibody. We also found that most Neurog3+ cells displayed undetectable or very low Tcf7l2 levels, 
except for a few cells where co-expression was evident (Fig. 7c), suggesting a transition between expression of 
these proteins. Marginal Tcf7l2 expression was also observed in cells expressing high levels of Foxa2 located 
within or adjacent to Tcf7l2 positive epithelial chords, which correspond to cells at early stages of endocrine dif-
ferentiation23 (Fig. 7d). Likewise, Tcf7l2 was co-expressed with Nkx6-1 in epithelial chords but was low in some 
cells exhibiting high Nkx6-1 levels, which likely correspond to differentiating β -cells (Fig. 7e). Remarkably, robust 
Tcf7l2 signal was detected in Nkx2-2-low trunk progenitors. Conversely, cells expressing Nkx2-2 (differentiating 
endocrine compartment) exhibited low or absent Tcf7l2 expression (Fig. 7f), revealing a well-defined mutually 
exclusive pattern of expression of these two transcription factors that would be in agreement with negative regu-
lation of Nkx2-2 by Tcf7l2.
Lastly, to confirm the immunostaining data, we determined Tcf7l2 mRNA levels in Neurog3 + progenitors 
and their descendants using FACS-purified tdT+ cells from Neurog3-Cre;tdT embryos. Tcf7l2 was expressed in 
tdT+ cells but its levels were reduced by 53% relative to tdT- (non-endocrine) cells. Strikingly, all LEF/TCF genes 
appeared to be downregulated in endocrine cells relative to the non-endocrine compartment (Fig. 7g). Since most 
Neurog3+ cells had very low or undetectable Tcf7l2 protein levels (Fig. 7c), we reasoned that Tcf7l2 expression 
decayed at the time of or shortly after endocrine specification. Interestingly, we observed that forced expression of 
Neurog3 reduced mRNA and protein levels of Tcf7l2 in mPAC cells (Fig. 7h,i), thus supporting a direct connec-
tion between activation of endocrine differentiation and downregulation of Tcf7l2 expression.
In sum, these findings reveal that Tcf7l2 levels decline in endocrine-committed progenitors and in the dif-
ferentiating endocrine compartment relative to cells within the epithelial progenitor chords at E15.5. Therefore, 
reduced Tcf7l2 gene expression is compatible with enhanced endocrine differentiation in Wnt9a-ablated 
pancreases.
Discussion
The function of the Wnt signalling pathway is highly dependent on cell context, and this dependency relies in 
part on its ligands and receptors, which display high lineage-specificity and are the most dynamically regulated 
components of the pathway during development35. However, many of the studies aimed at investigating the role 
of Wnt signalling in pancreas formation have used genetic manipulation of common core machinery, namely 
β -catenin, which may have masked more subtle cell type-specific and stage-dependent effects of this pathway. 
In the current study we aimed at defining the involvement of Wnt signals in endocrine cell formation through 
the investigation of the ligand Wnt9a, whose gene we identified as a target of the pro-endocrine transcription 
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Figure 6. Regulation of the Nkx2-2 gene by Tcf7l2. (a) mPAC cells were treated with the indicated 
adenoviruses (bGal, Neurog3 or TCF7L2) and total cellular RNA and/or total protein extracts were prepared 
48 h after virus treatment. mRNA levels for the indicated genes were measured by qRT-PCR and expressed 
relative to tbp. Data is expressed relative to levels in cells treated with AdV-bGal. Bars represent mean ± SEM for 
4 independent experiments. ND = not detectable (Ct > 36). *p < 0.05 **p < 0.01 vs Bgal. (b) INS1E cells were 
treated with increasing amounts of the adenovirus encoding TCF7L2 and total cellular RNA was extracted 24 h 
after virus treatment. Gene expression for Tcf7l2 (primers amplify both endogenous and adenovirally-expressed 
gene), Nkx2-2 and Pdx1 were measured by qRT-PCR and expressed relative to tbp gene expression. Bars represent 
mean ± SEM for 3-4 independent experiments. (c) Double immunofluorescence staining for TCF7L2 (green) 
and Nkx2-2 (red) in INS1 cells 24 h after transduction with an adenovirus encoding human TCF7L2. Arrows 
point to cells expressing adenovirally-expressed TCF7L2. Note that endogenous Tcf7l2 levels were undetectable.
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factor Neurog3 in cultured cells. Interestingly, publicly available gene expression profiling data shows that 
Wnt9a expression is higher in Neurog3+ than in Sox9+ (bipotent duct/endocrine progenitors) cells at E15.5 
(GEO ID = GDS4335: 10376490), consistent with this ligand being activated downstream of Neurog3. Whether 
Neurog3 regulates the Wnt9a gene directly or indirectly remains to be determined. It is noteworthy that both 
Wnt9a and Wnt7b (also identified as a Neurog3 target in our microarray analysis) were predicted as potential 
direct transcriptional targets of Neurogenin/NeuroD factors during neurogenesis using an informatics-based 
screening approach36.
The phenotype of Wnt9a mutants exposes a negative effect of this ligand in endocrine cell genesis, thus sug-
gesting that Wnt9a functions in a negative feedback loop to limit Neurog3 activity in vivo. Indeed, the absence 
of changes in pancreas growth, endocrine cell specification or endocrine cell proliferation in Wnt9a mutants is 
compatible with a role of Wnt9a during activation of the endocrine program downstream of Neurog3. Based 
on the findings presented here, we propose a model whereby levels of the Wnt effector Tcf7l2 need to be down 
regulated in endocrine progenitors to permit effective activation of the endocrine program. In this scenario, 
Wnt9a-dependent signalling, via positive regulation of Tcf7l2 expression/activity, would work as a control brake 
for endocrine differentiation (Fig. 8). Both in vivo and in vitro evidences point to Nkx2-2, whose requirement 
for correct endocrine cell development has been long established37, as an important target of the Wnt9a-Tcf7l2 
Figure 7. Expression patterns of Tcf7l2 in the embryonic pancreas during the secondary transition. (a–f) 
Co-immunostaining of Tcf7l2 (green) with: (a) Pdx1 (red); (b) insulin (red); (c) Neurog3 (red); (d) Foxa2 (red); 
(e) Nkx6-1 (red) and (f) Nkx2-2 (red); on paraffin sections of pancreas from Wnt9a+/+ and Wnt9a−/− embryos 
at E15.5. Arrowheads depict cells expressing Pdx1 (a), Neurog3 (c) or Foxa2 (d) and very low or undetectable 
Tcf7l2. Arrows in c depict cells where Neurog3 and Tcf7l2 appear to be co-expressed. Scale bars are 50 μ m. 
(g) mRNA levels for the indicated genes were quantitated in FACS-purified Tomato + (endocrine) cells obtained 
from E15.5 pancreas of Neurog3-Cre; Rosa26: tdTomato. Results are expressed relative to values in Tomato- 
cells isolated in the same experiments (value of 1). Bars represent mean ± SEM for 5 independent sorting 
experiments. Transcript levels for Ptf1a and Neurog3 are shown to illustrate non-endocrine vs. endocrine 
marker enrichment of Tomato + cells. (h-i) mPAC cells were treated with the indicated adenoviruses (bGal or 
Neurog3) and total cellular RNA and total protein extracts were prepared 48 h after virus treatment. (h) Tcf7l2 
mRNA levels were measured by qRT-PCR and expressed relative to tbp gene expression. Bars represent 
mean ± SEM for 8 independent experiments. (i) Immunoblot analysis of Tcf7l2 protein levels. Densitometric 
values were normalized to Tubulin and expressed relative to cells transduced with AdV-Bgal, which were given 
the value of 1. Bars represent mean ± SEM for 6 independent experiments. **p < 0.01 vs Bgal.
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pathway in the embryonic pancreas, although additional targets cannot be ruled out. If we assume that this 
model is correct and consider that not all cells that turn on Neurog3 expression ultimately become endocrine 
cells38, it can be speculated that under the Wnt9a-null condition, endocrine differentiation would be facilitated in 
cells that would otherwise revert to alternate (exocrine) fates, i.e cells that turn on a low level of Neurog338. The 
down-regulation of ductal gene expression in Wnt9a- ablated pancreases further supports the contribution of this 
ligand to fine-tuning activation of endocrine versus ductal cell programs in the pancreas.
Prior studies have demonstrated a role of another signalling pathway, the Notch pathway, in the regulation of 
the endocrine/ductal binary fate decision24. Interestingly, we have found that Notch ligand genes are upregulated 
in Wnt9a-ablated pancreases (GP, RG unpublished observations), which suggests that Notch may be involved 
in the effects of Wnt9a in the pancreas. The interplay Wnt-Notch is often seen in development39 and Notch lig-
ands have been identified as Wnt targets in several contexts40–43. Since Neurog3 regulates Notch ligand gene 
expression21,44,45, it appears that a complex network of cross-regulatory interactions between Neurog3 and these 
signalling pathways controls endocrine cell fate acquisition in the pancreas. Future work is needed to determine 
the molecular underpinnings of this network at a cell-based resolution in models with single and combined 
tissue-specific manipulations.
Genetic variations of the gene coding for TCF7L2 have been associated with type 2 diabetes in humans46. 
Remarkably, the TCF7L2 variant conferring the strongest risk for diabetes is suspected to exert its effects through 
increasing transcriptional activity of the TCF7L2 gene47,48. However, the molecular mechanisms implicated 
remain unresolved. Whilst many studies have focused on the function of TCF7L2 in adult β -cells49–52, little is 
known with regards to the role of this factor during pancreatic development. Global deletion of the Tcf7l2 gene 
in the mouse leads to perinatal mortality due to hepatic alterations, but endocrine cell formation is apparently 
normal53. Likewise, conditional deletion of Tcf7l2 in the pancreas and in β -cells has no seeming impact on adult 
β -cell mass at least under normal physiological growth53–55. However, detailed characterization of endocrine dif-
ferentiation in embryonic stages or neonatal endocrine cell counts was not provided in either study. Intriguingly, 
two recent investigations have shown that expression of dominant negative versions of Tcf7l2 in embryonic 
β -cells results in decreased β -cell mass and altered β -cell gene expression56,57. Our present findings provide 
additional support for a negative role of Tcf7l2 during pancreatic endocrine cell genesis that warrants further 
investigations. Tcf7l2 is a very complex protein that exhibits multiple isoforms and can act both as repressor or 
activator depending not only on the balance of the Tcf7l2 isoforms expressed at a given time and cell58, but also 
on post-translational modifications and available binding partners58–60. In this regard it is of note that Groucho/
Tle proteins, which are recruited by TCF factors and mediate their repressor function, have been shown to be 
pivotal for endocrine differentiation downstream of Neurog361. Further experiments aimed at the comprehensive 
Figure 8. Proposed model for regulation of endocrine differentiation by Wnt9a. The proposed model 
is based on (1) Neurog3 upregulates expression of the Nkx2-2 and Wnt9a genes and (2) Tcf7l2 negatively 
regulates the Nkx2-2 gene. Hence, in Neurog3+ cells, Wnt9a signalling would increase Tcf7l2 activity thus 
reducing Neurog3-dependent induction of the Nkx2-2 gene and serving as a control brake for activation of the 
endocrine program. In Wnt9a knockout animals, loss of Wnt9a would lead to reduced Tcf7l2 and enhanced 
Nkx2-2 expression. Additionally, Wnt9a may exert a paracrine effect and reinforce alternative non-endocrine 
fates by maintaining high Tcf7l2 expression/activity in neighbor cells. Note that Neurog3 may also have a direct 
repressive role on Tcf7l2 expression, which would ultimately help reinforce activation of the endocrine program 
in cells expressing sufficient levels of this pro-endocrine factor. Dashed lines indicate regulatory links where 
precise molecular mechanisms remain to be defined.
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analysis of the distribution of Tcf7l2 isoforms and the cellular context in which these variants are expressed in 
specific cell populations of the developing pancreas are needed to shed light into this issue.
In conclusion, this study places Wnt9a in the context of endocrine differentiation highlighting the notion that 
signalling ligands regulated by lineage-promoting factors may function as fine-tuners of developmental decisions 
promoted by these same factors. The present findings warrant further studies on the molecular circuitry govern-
ing Tcf7l2 activity in the embryonic pancreas and its potential implications for diabetes susceptibility. In addition, 
these data may also have important repercussions in our quest to improve β -cell differentiation protocols aimed 
at generating surrogate β -cells for transplantation purposes.
Methods
Mice. Mice were bred and maintained at the barrier animal facility of the University of Barcelona. Embryonic 
tissues were collected at indicated times, considering the morning of the appearance of a vaginal plug as embry-
onic day (E) 0.5. Principles of laboratory animal care were followed (European and local government guide-
lines) and animal procedures were approved by the Animal Research Committee of the University of Barcelona. 
Animals were euthanized by cervical dislocation. Mouse strains included Wnt9a+/lacZ mice16, membrane-tar-
geted tdTomato62 (Jackson Laboratory, Bar Harbor, ME, USA); Pdx1-Cre recombinase (Cre)63 and Neurog3-Cre64 
(Jackson Laboratory). Mice were genotyped with primers provided in Supplementary Table S2.
X-gal staining. Embryos were harvested and pancreas and gut were dissected and fixed for 1 h in fixative 
solution (2% PFA, 0.2% glutaraldehyde, 5 mM EGTA, 2 mM MgCl2 in 0.1 M phosphate pH7.3), washed in PBS, 
passed through 30% sucrose overnight and frozen in OCT. 15 μ m cryosections were stained with X-gal solution 
containing detergent65 for 48 h at 37 °C.
Pancreatic cell dispersion and flow cytometry. Pancreatic buds were harvested from E14.5-E15.5 
embryos and treated with 0.125% trypsin-EDTA (Life Technologies) and 50 ng/ml Dnase I with agitation for 
10–15 min at 37 °C. Digestion was inactivated by addition of RPMI-1640/10%FCS. Cells were recovered by cen-
trifugation and resuspended in RPMI-1640/3%FCS for sorting using a BD FACSAria SORP machine.
Cell culture and viral treatment. mPAC cells were grown in DMEM-4.5 g/L glucose (Sigma-Aldrich, St 
Louis, MO, USA) plus antibiotics supplemented with 10% fetal bovine serum. INS1E cells were cultured in RPMI-
1640 medium supplemented with 10% fetal bovine serum, 10 mM Hepes, 2 mM L-glutamine, 1 mM sodium pyru-
vate and 50 μ M β -mercaptoethanol. For adenoviral transduction experiments, cells were seeded onto 6-well plates 
and treated one day later with adenoviruses at a multiplicity of infection (moi) of 40 unless otherwise indicated 
for 2 h. Then, virus containing-media was replaced and cells were cultured for the indicated periods.
The coding sequence of the mouse Wnt9a cDNA was amplified from embryonic (E15.5) brain with the prim-
ers listed in Supplementary material and cloned into the adenoviral pAC.CMV shuttle vector. The recombinant 
adenovirus was constructed by homologous recombination in HEK293 cells. The adenovirus encoding human 
TCF7L253 was kindly provided by Dr. C. Fillat (IDIBAPS, Barcelona, Spain). All other adenoviruses were previ-
ously described21,65.
RNA isolation and RT-PCR analysis. Total RNA was isolated from cell lines or tissues using the RNeasy 
kit (Qiagen, Hilden, Germany) and from sorted cells using the NucleoSpin XS RNA kit (Mackerey-Nagel, Düren, 
Germany). First-strand cDNA was prepared using the Superscript III RT kit and random hexamer primers 
(Invitrogen, Carlsbad, CA, USA). Reverse transcription reaction was carried for 90 min at 50 °C and an additional 
10 min at 55 °C. Real time PCR (qRT-PCR) was performed on an ABI Prism 7900 sequence detection system using 
SybrGreen reagents (Express Greener, Invitrogen). Primer sequences are provided in Supplementary Table S2.
Transient transfections and luciferase assays. 1.5 × 104 mPAC cells were plated onto 96-well culture 
tissue plates one day before transfection. Transient transfections were performed using Metafectene (Biontex 
Laboratories GmbH, Martinsried, Germany) according to the manufacturer’s instructions. The amount of DNA 
used per well were: 250 ng of firefly luciferase reporter vectors, 2.5 ng of pRL.CMV and 5–20 ng of expression 
vector. Empty expression vector was added when necessary to keep the amount of DNA equal in all wells. Cells 
were harvested 48 h after transfection and luciferase activity was analyzed using the Dual-Luciferase Reporter 
Assay System (Promega) and a Veritas microplate luminometer (Promega). Luciferase readings were normalized 
to activities of the internal control vector pRL.CMV.
The mouse Wnt9a cDNA (see above) was cloned into the EcoRI/XbaI sites of the pCMV-TNT vector 
(Promega). The expression vectors (pCIG backbone) encoding a mutant form of β -catenin lacking aminoac-
ids 29–48 and mouse Wnt3a were kindly provided by Dr. E.Martí (IBMB-CSIC, Barcelona, Spain). The lucif-
erase reporter vectors Super8xTOPFlash and FOPFlash were kindly provided by Dr. R.T. Moon (University of 
Washington, Seatle, WA, USA). The Renilla luciferase reporter plasmid pRL-CMV was from Promega.
Immunoblotting. Cells and embryonic pancreases were lysed in triple detergent lysis buffer (Tris-HCl 
50 mM, NaCl 150 mM, 0.1% SDS, 1% NP40 and 0.5% Sodium Deoxycholate). 50 μ g of lysates were separated by 
PAGE-SDS electrophoresis, transferred to a Polyscreen PVDF membrane (Perkin Elmer, Waltham, MA, USA) 
and incubated overnight at 4 °C with the antibodies indicated in Supplementary Table S3. Blots were visualized 
with ECL Reagent (Pierce Biotechnology, Rockford, IL, USA) using a LAS4000 Lumi-Imager (Fuji Photo Film, 
Valhalla, NY). Protein spots were quantitated with Image J software (http://rsb.info.nih.gov/ij/index.html).
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Immunofluorescence and morphometric analysis. Mouse embryos were fixed in 4% paraformalde-
hyde (PFA) for 3–6h. Tissues were subsequently washed, dehydrated, embedded in paraffin wax, and sectioned 
at 3 μ m. For immunofluorescence, a standard immunodetection protocol was followed as described in23. Briefly, 
tissues were rehydrated and, when required, subjected to heat-mediated antigen retrieval in citrate buffer. After 
a blocking step in 5% donkey serum/ 0.2% Triton X-100, tissue sections were incubated overnight with pri-
mary antibodies and then for 1 h with secondary antibodies (Supplementary Table S3). Nuclei were stained with 
Hoechst 33258 (Sigma). Fluorescent images were captured using a Leica DMI 6000B widefield microscope or 
a Leica TCS SPE confocal microscope. For morphometrical analysis, total pancreas was sectioned at 3 μ m and 
distributed as serial sections onto sets of 5 slides. At least 10 sections 45 μ m apart per animal were analyzed using 
Image J software (http://rsb.info.nih.gov/ij/index.html).
INS1E cells were fixed in 4% PFA for 20 min at room temperature and permeabilized in PBS with 0.2% Triton 
X-100. After a blocking step of 1 h in 3% normal donkey serum, cells were incubated overnight with the indicated 
primary antibodies. After washes, cells were incubated with the secondary antibodies for 1 h at RT and. nuclei 
were stained for 3 min in a 1:500 dilution of Hoechst 33258 (Sigma).
Statistical analysis. Data are presented as mean ± standard error of the mean (SEM). Statistical significance 
was tested using Student’s t-test.
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